Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies ; volume:14 ; number:1 ; day:7 ; month:2 ; year:2024 ; pages:1-13 ; date:12.2024
Scientific reports ; 14, Heft 1 (7.2.2024), 1-13, 12.2024
- Urheber
-
Brandi, Giovanni
Relli, Valeria
Deserti, Marzia
Palloni, Andrea
Indio, Valentina
Astolfi, Annalisa
Serravalle, Salvatore
Mattiaccio, Alessandro
Vasuri, Francesco
Malvi, Deborah
Deiana, Chiara
Pantaleo, Maria Abbondanza
Cescon, Matteo
Rizzo, Alessandro
Katoh, Masaru
Tavolari, Simona
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-52991-8
- URN
-
urn:nbn:de:101:1-2404160818230.721264806980
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Brandi, Giovanni
- Relli, Valeria
- Deserti, Marzia
- Palloni, Andrea
- Indio, Valentina
- Astolfi, Annalisa
- Serravalle, Salvatore
- Mattiaccio, Alessandro
- Vasuri, Francesco
- Malvi, Deborah
- Deiana, Chiara
- Pantaleo, Maria Abbondanza
- Cescon, Matteo
- Rizzo, Alessandro
- Katoh, Masaru
- Tavolari, Simona
- SpringerLink (Online service)
Ähnliche Objekte (12)
Transarterial Therapies for the Treatment of Intrahepatic Cholangiocarcinoma
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
A murine model of FGFR2 fusion driven intrahepatic cholangiocarcinoma to delineate the mechanism of therapeutic response and resistance to FGFR inhibitors
MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma
Benchmarks in Liver Resection for Intrahepatic Cholangiocarcinoma
The focus clinical research in intrahepatic cholangiocarcinoma
Prognostic factors in patients with intrahepatic cholangiocarcinoma
Differential enrichment of H3K9me3 in intrahepatic cholangiocarcinoma
Precision oncology for intrahepatic cholangiocarcinoma in clinical practice
Maffucci Syndrome with Intrahepatic Cholangiocarcinoma: A Case Report
Transarterial Therapies for the Treatment of Intrahepatic Cholangiocarcinoma
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
A murine model of FGFR2 fusion driven intrahepatic cholangiocarcinoma to delineate the mechanism of therapeutic response and resistance to FGFR inhibitors
MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma
Benchmarks in Liver Resection for Intrahepatic Cholangiocarcinoma
The focus clinical research in intrahepatic cholangiocarcinoma
Prognostic factors in patients with intrahepatic cholangiocarcinoma
Differential enrichment of H3K9me3 in intrahepatic cholangiocarcinoma
Precision oncology for intrahepatic cholangiocarcinoma in clinical practice
Maffucci Syndrome with Intrahepatic Cholangiocarcinoma: A Case Report
Transarterial Therapies for the Treatment of Intrahepatic Cholangiocarcinoma
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
A murine model of FGFR2 fusion driven intrahepatic cholangiocarcinoma to delineate the mechanism of therapeutic response and resistance to FGFR inhibitors
MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma
Benchmarks in Liver Resection for Intrahepatic Cholangiocarcinoma
The focus clinical research in intrahepatic cholangiocarcinoma
Prognostic factors in patients with intrahepatic cholangiocarcinoma
Differential enrichment of H3K9me3 in intrahepatic cholangiocarcinoma
Precision oncology for intrahepatic cholangiocarcinoma in clinical practice